<DOC>
	<DOCNO>NCT01309295</DOCNO>
	<brief_summary>This prospective observational study assess efficacy safety Mircera ( methoxy polyethylene glycol-epoetin beta ) clinical practice patient chronic kidney disease , pre-dialysis dialysis , initiate Mircera treatment . Data patient collect 12 month treatment .</brief_summary>
	<brief_title>An Observational Study Mircera ( Methoxy Polyethylene Glycol-Epoetin Beta ) Patients With Chronic Kidney Disease Pre-Dialysis Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Chronic kidney disease , predialysis dialysis Appropriate treatment Mircera accord current guideline Summary Product Characteristics Anemia due nonrenal cause Pregnant lactate woman Uncontrolled hypertension Known hypersensitivity methoxy polyethylene glycolepoetin beta</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>